Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Crispr Therapeutics Ag
(NQ:
CRSP
)
47.85
-1.00 (-2.05%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Crispr Therapeutics Ag
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
3 Growth Stocks You’ll Kick Yourself for Not Buying Today
May 03, 2024
Netflix, Intuit, and Vertex Pharmaceuticals are three growth stocks to buy, each positioned for significant market share and returns.
Via
InvestorPlace
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
May 02, 2024
It pays to develop novel medicines for life-threatening illnesses.
Via
The Motley Fool
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
May 02, 2024
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion.
Via
InvestorPlace
Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge
May 01, 2024
A slip in the market could give investors a rare opportunity to get some top biotech stocks to buy at a considerable discount.
Via
InvestorPlace
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
April 24, 2024
Good news could be just around the corner for two drugmakers not named Novo Nordisk.
Via
The Motley Fool
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today
March 19, 2024
Via
Benzinga
Is It Too Late to Buy CRISPR Therapeutics Stock?
March 16, 2024
The biotech has been making a lot of noise since late last year.
Via
The Motley Fool
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
April 23, 2024
Vertex is broadening its portfolio.
Via
The Motley Fool
3 Magnificent Stocks That Could Double or More by 2030
April 13, 2024
There's no guarantee these stocks will double by 2030, but their growth prospects look great.
Via
The Motley Fool
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
April 11, 2024
In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024.
Via
InvestorPlace
Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics
April 09, 2024
These rising drugmakers have serious arguments in their favor.
Via
The Motley Fool
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
April 09, 2024
These stocks, a bargain today, are players to hold on to for the long term.
Via
The Motley Fool
Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics
April 05, 2024
These companies are in the early days of their growth stories.
Via
The Motley Fool
3 Unstoppable Stocks to Buy Hand Over Fist in April
March 30, 2024
These stocks have exceptionally bright prospects.
Via
The Motley Fool
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why
March 28, 2024
The company is working to launch its Vertex-partnered gene-editing drug for sickle cell disease and beta thalassemia.
Via
Investor's Business Daily
3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition
March 28, 2024
Discover these three biotech stocks set for major gains with groundbreaking health solutions. Invest in the future of medicine.
Via
InvestorPlace
3 No-Brainer Healthcare Stocks to Buy Right Now for Less Than $1,000
March 27, 2024
Each of these three companies are entering a new era of growth.
Via
The Motley Fool
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
March 23, 2024
The price could be right for these three biopharma stocks.
Via
The Motley Fool
3 Stocks That Could Be the Next Big Thing in Gene Editing
March 21, 2024
Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks.
Via
InvestorPlace
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
March 20, 2024
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel
Via
MarketBeat
Exposures
Product Safety
The 3 Most Undervalued Cathie Wood Stocks to Buy in March 2024
March 15, 2024
These undervalued Cathie Wood stocks capture her favorite trends and remain undervalued even as the wider tech sector surge.
Via
InvestorPlace
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
March 13, 2024
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.
Via
InvestorPlace
Cathie Wood's Ark Invest Keeps Dumping Coinbase Shares Amid Bitcoin, Crypto Buzz
March 12, 2024
On Tuesday, Cathie Wood-led Ark Invest made a significant move by offloading a substantial number of shares in Coinbase Global Inc (NASDAQ:COIN), despite Bitcoin (CRYPTO: BTC) reaching new
Via
Benzinga
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility
March 11, 2024
Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23.
Via
Talk Markets
The Top 3 Biotech Stocks to Buy in March 2024
March 06, 2024
Although the biotech sector puts the benefits and risks in plain sight, three top biotech stocks to buy shine for investors.
Via
InvestorPlace
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
March 06, 2024
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place
Via
MarketBeat
Here's Why CRISPR Therapeutics Stock Climbed 34% in February
March 05, 2024
The biotech company keeps moving closer to bringing its promising first gene therapy to market.
Via
The Motley Fool
ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential
March 04, 2024
Here are three ChatGPT stock predictions for the most unpredictable of biotech stocks that might just have 10x potential.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
MarketBeat Week in Review – 2/26 - 3/1
March 02, 2024
As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst
February 29, 2024
This company's fortunes are likely to improve, and soon.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.